Impact of androgen deprivation therapy (ADT) on circulating tumor DNA (ctDNA) detection in de novo metastatic castration-sensitive prostate cancer (mCSPC).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.204
Abstract: 204 Background: Plasma ctDNA is detected in most patients with metastatic castration-resistant prostate cancer, enabling minimally invasive tumor genotyping that informs prognosis and therapy decisions. However, most patients with de novo mCSPC will commence ADT… read more here.
Keywords: detection; novo mcspc; ctdna detection; adt ... See more keywords